Astellas to Establish Joint Venture with YASKAWA for Cell Therapy Manufacturing
Shots:
- Astellas has entered into definitive agreement with YASKAWA to establish a joint venture for the development of a cell therapy product manufacturing platform based on previously signed MoU (May 21, 2024)
- In joint venture, Astellas will own 60% & YASKAWA 40% with $30.14M (¥4.5B) capital & expected to establish in Sept 2025, subject to pending regulatory approvals & closing conditions
- Joint entity will leverage Astellas' R&D & manufacturing expertise with YASKAWA's dual-arm robot Maholo to optimize precision manufacturing, enable one-click GMP-compliant process transfer, & develop cell therapies for partners while fostering collaboration with startups & academic institutions
Ref: Astellas | Image: Astellas & YASKAWA
Related News:- Japan’s MHLW Receives NDA for Conditional Approval of Astellas’ Avacincaptad Pegol to Treat Geographic Atrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
